BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 35963298)

  • 1. Novel compound ZCJ14, a gefitinib analog, exhibited prominent anti-cancer effect among several cancer cell lines.
    Wang J; Yan PP; Wang HY; Zuo SJ; Zhang SQ; Cao YX; Cao L
    Life Sci; 2022 Oct; 307():120875. PubMed ID: 35963298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer.
    Sun C; Gao W; Liu J; Cheng H; Hao J
    Respir Res; 2020 Aug; 21(1):210. PubMed ID: 32778129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
    Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC
    PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel EGFR inhibitor suppresses survivin expression and tumor growth in human gefitinib-resistant EGFR-wild type and -T790M non-small cell lung cancer.
    Wang SP; Hsu YP; Chang CJ; Chan YC; Chen CH; Wang RH; Liu KK; Pan PY; Wu YH; Yang CM; Chen C; Yang JM; Liang MC; Wong KK; Chao JI
    Biochem Pharmacol; 2021 Nov; 193():114792. PubMed ID: 34597670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo.
    Zhang K; Wang L; Wei A; Jia X; Liu X
    Thorac Cancer; 2020 Jun; 11(6):1566-1577. PubMed ID: 32368855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
    Li A; Cao W; Liu X; Zhang Y; Ma Y; Xu R; Zhang R; Liu X; Zhou S; Wang R; Liu J; Tang X
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1737-1749. PubMed ID: 32342201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of gefitinib-1,2,3-triazole derivatives against lung cancer via inducing apoptosis and inhibiting the colony formation.
    Gao E; Wang Y; Fan GL; Xu G; Wu ZY; Liu ZJ; Liu JC; Mao LF; Hou X; Li S
    Sci Rep; 2024 Apr; 14(1):9223. PubMed ID: 38649732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo.
    Liu Z; Gao W
    Arch Toxicol; 2019 Jun; 93(6):1555-1571. PubMed ID: 30993382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
    BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chelidonine selectively inhibits the growth of gefitinib-resistant non-small cell lung cancer cells through the EGFR-AMPK pathway.
    Xie YJ; Gao WN; Wu QB; Yao XJ; Jiang ZB; Wang YW; Wang WJ; Li W; Hussain S; Liu L; Leung EL; Fan XX
    Pharmacol Res; 2020 Sep; 159():104934. PubMed ID: 32464330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of S-1 and gefitinib increases the sensitivity to radiotherapy in lung cancer cells.
    Cui J; Wang MC; Zhang YM; Ren MZ; Wang SX; Nan KJ; Song LP
    Cancer Chemother Pharmacol; 2018 Apr; 81(4):717-726. PubMed ID: 29480364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SOX9 promotes epidermal growth factor receptor-tyrosine kinase inhibitor resistance via targeting β-catenin and epithelial to mesenchymal transition in lung cancer.
    Tripathi SK; Biswal BK
    Life Sci; 2021 Jul; 277():119608. PubMed ID: 33989664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.
    Zheng Q; Dong H; Mo J; Zhang Y; Huang J; Ouyang S; Shi S; Zhu K; Qu X; Hu W; Liu P; Wang Y; Zhang X
    Theranostics; 2021; 11(2):824-840. PubMed ID: 33391507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFR
    Wang G; Zhao J; Zhang M; Wang Q; Chen B; Hou Y; Lu K
    Int J Nanomedicine; 2019; 14():4503-4515. PubMed ID: 31417255
    [No Abstract]   [Full Text] [Related]  

  • 15. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
    Dong S; Qu X; Li W; Zhong X; Li P; Yang S; Chen X; Shao M; Zhang L
    J Hematol Oncol; 2015 Apr; 8():43. PubMed ID: 25925741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo.
    Zhu H; Cheng H; Ren Y; Liu ZG; Zhang YF; De Luo B
    Mol Biol Rep; 2012 Apr; 39(4):4971-9. PubMed ID: 22160570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acetylshikonin exerts anti-tumor effects on non-small cell lung cancer through dual inhibition of STAT3 and EGFR.
    Tang Y; Wang Y; Wang X; Zhao Z; Cai H; Xie M; Jiang X; Zhang L; Cheng J; Yang L; Wang L; Zhao C; Huang X
    Phytomedicine; 2022 Jul; 101():154109. PubMed ID: 35526322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET.
    Oh HN; Lee MH; Kim E; Yoon G; Chae JI; Shim JH
    Phytomedicine; 2019 Oct; 63():153014. PubMed ID: 31323446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
    Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
    Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer.
    Galvani E; Giovannetti E; Saccani F; Cavazzoni A; Leon LG; Dekker H; Alfieri R; Carmi C; Mor M; Ardizzoni A; Petronini PG; Peters GJ
    Neoplasia; 2013 Jan; 15(1):61-72. PubMed ID: 23359111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.